ParkinsonFranceV1, PascalFrancis, Corpus, bibRecord, 001A52

Apomorphine in treatment of Parkinson's disease : comparison between subcutaneous and sublingual routes

Identifieur interne : 001A52 ( PascalFrancis/Corpus ); précédent : 001A51; suivant : 001A53

Apomorphine in treatment of Parkinson's disease : comparison between subcutaneous and sublingual routes

Auteurs : D. Deffond ; F. Durif ; M. Tournilhac

Source :

Journal of neurology, neurosurgery and psychiatry [ 0022-3050 ] ; 1993.

RBID : Pascal:93-0385199

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Traitement, Homme, Chimiothérapie, Stimulant dopaminergique, Antiparkinsonien, Voie orale, Voie souscutanée, Apomorphine.

English descriptors

KwdEn :
- Antiparkinson agent, Chemotherapy, Dopamine agonist, Human, Oral administration, Parkinson disease, Subcutaneous administration, Treatment.

Abstract

The efficacy of two routes of apomorphine, subcutaneous (SC) and sublingual (SL), successively administered in 7 Parkinsonian patients with motor fluctuations, was compared in reducing the daily duration of «off» phases. The mean duration of SC and SL treatment was 7.77 and 6-8 months respectively. The mean time spent in «off» phase was 55% after SC and 68% after SL treatinent. The mean time before turning «on» after an «off» period was 14 minutes after SC and 28 minutes after SL treatment

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0022-3050`
A02	`01`			`@0 JNNPAU`
A03		`1`		`@0 J. neurol. neurosurg. psychiatry`
A05				`@2 56`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Apomorphine in treatment of Parkinson's disease : comparison between subcutaneous and sublingual routes`
A11	`01`	`1`		`@1 DEFFOND (D.)`
A11	`02`	`1`		`@1 DURIF (F.)`
A11	`03`	`1`		`@1 TOURNILHAC (M.)`
A14	`01`			`@1 Hôp. Fontmaure, clin. neurologique @2 63400 Chamaliéres @3 FRA`
A20				`@1 101-103`
A21				`@1 1993`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 6015 @5 354000038427550180`
A44				`@0 0000`
A45				`@0 14 ref.`
A47	`01`	`1`		`@0 93-0385199`
A60				`@1 P @3 CC`
A61				`@0 A`
A64		`1`		`@0 Journal of neurology, neurosurgery and psychiatry`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 The efficacy of two routes of apomorphine, subcutaneous (SC) and sublingual (SL), successively administered in 7 Parkinsonian patients with motor fluctuations, was compared in reducing the daily duration of «off» phases. The mean duration of SC and SL treatment was 7.77 and 6-8 months respectively. The mean time spent in «off» phase was 55% after SC and 68% after SL treatinent. The mean time before turning «on» after an «off» period was 14 minutes after SC and 28 minutes after SL treatment
C02	`01`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad`
C03	`02`	`X`	`FRE`	`@0 Traitement`
C03	`02`	`X`	`ENG`	`@0 Treatment`
C03	`02`	`X`	`GER`	`@0 Aufbereiten`
C03	`02`	`X`	`SPA`	`@0 Tratamiento`
C03	`03`	`X`	`FRE`	`@0 Homme`
C03	`03`	`X`	`ENG`	`@0 Human`
C03	`03`	`X`	`SPA`	`@0 Hombre`
C03	`04`	`X`	`FRE`	`@0 Chimiothérapie`
C03	`04`	`X`	`ENG`	`@0 Chemotherapy`
C03	`04`	`X`	`SPA`	`@0 Quimioterapia`
C03	`05`	`X`	`FRE`	`@0 Stimulant dopaminergique`
C03	`05`	`X`	`ENG`	`@0 Dopamine agonist`
C03	`05`	`X`	`SPA`	`@0 Estimulante dopaminérgico`
C03	`06`	`X`	`FRE`	`@0 Antiparkinsonien`
C03	`06`	`X`	`ENG`	`@0 Antiparkinson agent`
C03	`06`	`X`	`SPA`	`@0 Antiparkinsoniano`
C03	`07`	`X`	`FRE`	`@0 Voie orale`
C03	`07`	`X`	`ENG`	`@0 Oral administration`
C03	`07`	`X`	`SPA`	`@0 Vía oral`
C03	`08`	`X`	`FRE`	`@0 Voie souscutanée`
C03	`08`	`X`	`ENG`	`@0 Subcutaneous administration`
C03	`08`	`X`	`SPA`	`@0 Vía subcutánea`
C03	`09`	`X`	`FRE`	`@0 Apomorphine @2 NK @2 FR`
C07	`01`	`X`	`FRE`	`@0 Maladie dégénérative`
C07	`01`	`X`	`ENG`	`@0 Degenerative disease`
C07	`01`	`X`	`SPA`	`@0 Enfermedad degenerativa`
C07	`02`	`X`	`FRE`	`@0 Système nerveux pathologie`
C07	`02`	`X`	`ENG`	`@0 Nervous system diseases`
C07	`02`	`X`	`SPA`	`@0 Sistema nervioso patología`
N21				`@1 147`

Format Inist (serveur)

NO :	PASCAL 93-0385199 INIST
ET :	Apomorphine in treatment of Parkinson's disease : comparison between subcutaneous and sublingual routes
AU :	DEFFOND (D.); DURIF (F.); TOURNILHAC (M.)
AF :	Hôp. Fontmaure, clin. neurologique/63400 Chamaliéres/France
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Journal of neurology, neurosurgery and psychiatry; ISSN 0022-3050; Coden JNNPAU; Royaume-Uni; Da. 1993; Vol. 56; No. 1; Pp. 101-103; Bibl. 14 ref.
LA :	Anglais
EA :	The efficacy of two routes of apomorphine, subcutaneous (SC) and sublingual (SL), successively administered in 7 Parkinsonian patients with motor fluctuations, was compared in reducing the daily duration of «off» phases. The mean duration of SC and SL treatment was 7.77 and 6-8 months respectively. The mean time spent in «off» phase was 55% after SC and 68% after SL treatinent. The mean time before turning «on» after an «off» period was 14 minutes after SC and 28 minutes after SL treatment
CC :	002B02B06
FD :	Parkinson maladie; Traitement; Homme; Chimiothérapie; Stimulant dopaminergique; Antiparkinsonien; Voie orale; Voie souscutanée; Apomorphine
FG :	Maladie dégénérative; Système nerveux pathologie
ED :	Parkinson disease; Treatment; Human; Chemotherapy; Dopamine agonist; Antiparkinson agent; Oral administration; Subcutaneous administration
EG :	Degenerative disease; Nervous system diseases
GD :	Aufbereiten
SD :	Parkinson enfermedad; Tratamiento; Hombre; Quimioterapia; Estimulante dopaminérgico; Antiparkinsoniano; Vía oral; Vía subcutánea
LO :	INIST-6015.354000038427550180
ID :	93-0385199

Links to Exploration step

Pascal:93-0385199

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Apomorphine in treatment of Parkinson's disease : comparison between subcutaneous and sublingual routes</title>
<author><name sortKey="Deffond, D" sort="Deffond, D" uniqKey="Deffond D" first="D." last="Deffond">D. Deffond</name>
<affiliation><inist:fA14 i1="01"><s1>Hôp. Fontmaure, clin. neurologique</s1>
<s2>63400 Chamaliéres</s2>
<s3>FRA</s3>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Durif, F" sort="Durif, F" uniqKey="Durif F" first="F." last="Durif">F. Durif</name>
</author>
<author><name sortKey="Tournilhac, M" sort="Tournilhac, M" uniqKey="Tournilhac M" first="M." last="Tournilhac">M. Tournilhac</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">93-0385199</idno>
<date when="1993">1993</date>
<idno type="stanalyst">PASCAL 93-0385199 INIST</idno>
<idno type="RBID">Pascal:93-0385199</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001A52</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Apomorphine in treatment of Parkinson's disease : comparison between subcutaneous and sublingual routes</title>
<author><name sortKey="Deffond, D" sort="Deffond, D" uniqKey="Deffond D" first="D." last="Deffond">D. Deffond</name>
<affiliation><inist:fA14 i1="01"><s1>Hôp. Fontmaure, clin. neurologique</s1>
<s2>63400 Chamaliéres</s2>
<s3>FRA</s3>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Durif, F" sort="Durif, F" uniqKey="Durif F" first="F." last="Durif">F. Durif</name>
</author>
<author><name sortKey="Tournilhac, M" sort="Tournilhac, M" uniqKey="Tournilhac M" first="M." last="Tournilhac">M. Tournilhac</name>
</author>
</analytic>
<series><title level="j" type="main">Journal of neurology, neurosurgery and psychiatry</title>
<title level="j" type="abbreviated">J. neurol. neurosurg. psychiatry</title>
<idno type="ISSN">0022-3050</idno>
<imprint><date when="1993">1993</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of neurology, neurosurgery and psychiatry</title>
<title level="j" type="abbreviated">J. neurol. neurosurg. psychiatry</title>
<idno type="ISSN">0022-3050</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Dopamine agonist</term>
<term>Human</term>
<term>Oral administration</term>
<term>Parkinson disease</term>
<term>Subcutaneous administration</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Traitement</term>
<term>Homme</term>
<term>Chimiothérapie</term>
<term>Stimulant dopaminergique</term>
<term>Antiparkinsonien</term>
<term>Voie orale</term>
<term>Voie souscutanée</term>
<term>Apomorphine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The efficacy of two routes of apomorphine, subcutaneous (SC) and sublingual (SL), successively administered in 7 Parkinsonian patients with motor fluctuations, was compared in reducing the daily duration of «off» phases. The mean duration of SC and SL treatment was 7.77 and 6-8 months respectively. The mean time spent in «off» phase was 55% after SC and 68% after SL treatinent. The mean time before turning «on» after an «off» period was 14 minutes after SC and 28 minutes after SL treatment</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-3050</s0>
</fA01>
<fA02 i1="01"><s0>JNNPAU</s0>
</fA02>
<fA03 i2="1"><s0>J. neurol. neurosurg. psychiatry</s0>
</fA03>
<fA05><s2>56</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Apomorphine in treatment of Parkinson's disease : comparison between subcutaneous and sublingual routes</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>DEFFOND (D.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>DURIF (F.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>TOURNILHAC (M.)</s1>
</fA11>
<fA14 i1="01"><s1>Hôp. Fontmaure, clin. neurologique</s1>
<s2>63400 Chamaliéres</s2>
<s3>FRA</s3>
</fA14>
<fA20><s1>101-103</s1>
</fA20>
<fA21><s1>1993</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>6015</s2>
<s5>354000038427550180</s5>
</fA43>
<fA44><s0>0000</s0>
</fA44>
<fA45><s0>14 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>93-0385199</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i2="1"><s0>Journal of neurology, neurosurgery and psychiatry</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The efficacy of two routes of apomorphine, subcutaneous (SC) and sublingual (SL), successively administered in 7 Parkinsonian patients with motor fluctuations, was compared in reducing the daily duration of «off» phases. The mean duration of SC and SL treatment was 7.77 and 6-8 months respectively. The mean time spent in «off» phase was 55% after SC and 68% after SL treatinent. The mean time before turning «on» after an «off» period was 14 minutes after SC and 28 minutes after SL treatment</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Traitement</s0>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Treatment</s0>
</fC03>
<fC03 i1="02" i2="X" l="GER"><s0>Aufbereiten</s0>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Tratamiento</s0>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Homme</s0>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Human</s0>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Hombre</s0>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Chimiothérapie</s0>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Chemotherapy</s0>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Quimioterapia</s0>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Dopamine agonist</s0>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Voie orale</s0>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Oral administration</s0>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Vía oral</s0>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Voie souscutanée</s0>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Subcutaneous administration</s0>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Vía subcutánea</s0>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Apomorphine</s0>
<s2>NK</s2>
<s2>FR</s2>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Degenerative disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
</fC07>
<fN21><s1>147</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 93-0385199 INIST</NO>
<ET>Apomorphine in treatment of Parkinson's disease : comparison between subcutaneous and sublingual routes</ET>
<AU>DEFFOND (D.); DURIF (F.); TOURNILHAC (M.)</AU>
<AF>Hôp. Fontmaure, clin. neurologique/63400 Chamaliéres/France</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Journal of neurology, neurosurgery and psychiatry; ISSN 0022-3050; Coden JNNPAU; Royaume-Uni; Da. 1993; Vol. 56; No. 1; Pp. 101-103; Bibl. 14 ref.</SO>
<LA>Anglais</LA>
<EA>The efficacy of two routes of apomorphine, subcutaneous (SC) and sublingual (SL), successively administered in 7 Parkinsonian patients with motor fluctuations, was compared in reducing the daily duration of «off» phases. The mean duration of SC and SL treatment was 7.77 and 6-8 months respectively. The mean time spent in «off» phase was 55% after SC and 68% after SL treatinent. The mean time before turning «on» after an «off» period was 14 minutes after SC and 28 minutes after SL treatment</EA>
<CC>002B02B06</CC>
<FD>Parkinson maladie; Traitement; Homme; Chimiothérapie; Stimulant dopaminergique; Antiparkinsonien; Voie orale; Voie souscutanée; Apomorphine</FD>
<FG>Maladie dégénérative; Système nerveux pathologie</FG>
<ED>Parkinson disease; Treatment; Human; Chemotherapy; Dopamine agonist; Antiparkinson agent; Oral administration; Subcutaneous administration</ED>
<EG>Degenerative disease; Nervous system diseases</EG>
<GD>Aufbereiten</GD>
<SD>Parkinson enfermedad; Tratamiento; Hombre; Quimioterapia; Estimulante dopaminérgico; Antiparkinsoniano; Vía oral; Vía subcutánea</SD>
<LO>INIST-6015.354000038427550180</LO>
<ID>93-0385199</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A52 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001A52 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:93-0385199
   |texte=   Apomorphine in treatment of Parkinson's disease : comparison between subcutaneous and sublingual routes
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Apomorphine in treatment of Parkinson's disease : comparison between subcutaneous and sublingual routes

Apomorphine in treatment of Parkinson's disease : comparison between subcutaneous and sublingual routes

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri